New combo therapy aims to stop liver Cancer's comeback

This early-stage study is testing a new combination treatment to prevent liver cancer from returning or progressing. It combines a vaccine designed to train the immune system to attack cancer cells with an immunotherapy drug (durvalumab) that helps keep the immune response active. The trial is for patients with early to intermediate-stage liver cancer who have already finished their standard treatments and currently show no signs of active disease.